… Point estimate of relative risk of hepatic veno-occlusive disease (HVOD) and 95% confidence
interval in the 3 randomized trials comparing ursodeoxycholic acid with no treatment as …

… Hepatic veno‐occlusive disease (VOD) is a common transplant‐related complication of …
Limited studies have suggested that prophylactic use of ursodeoxycholic acid (UDCA) reduced …

… Prophylactic administration of ursodeoxycholic acid, being an antioxidant and antiapoptotic
agent, can have some benefit in reducing overall mortality. Defibrotide, which has pro-…

… [30•] conducted a randomized study of ursodiol in … ursodiol should prevent VOD is unclear.
It is postulated that the replacement of toxic hydrophobic bile acids with hydrophilic ursodiol …

… Veno-occlusive disease A recent study suggests that ursodeoxycholic acid treatment might
prevent hepatic veno-occlusive disease after bone marrow transplantation (46). This dreaded …

… ursodeoxycholic acid with no ursodeoxycholic acid[27]. Two of 71 patients (2.8%) in the
ursodeoxycholic acid … trial again compared ursodeoxycholic acid with no ursodeoxycholic acid[28…

… Ursodiol (ursodeoxycholic acid; UDCA) is a naturally occurring hydrophilic bile salt that
has shown efficacy in the treatment of some hepatic disorders. Recently, prophylactic use …

… E1, ursodiol, and glutamine have been studied for prevention of veno-occlusive disease. …
been clearly established in patients with veno-occlusive disease. Other possible treatment …

… The original definition of hepatic veno-occlusive disease (VOD), … Ursodeoxycholic acid was
used as VOD prophylaxis … , it is uncertain whether ursodiol or other common characteristics of …

… Ursodeoxycholic acid (ursodiol) beginning … ursodeoxycholic acid (ursodiol) reduces the
incidence of SOS in the HSCT population is equivocal.139, 140, 141, 142 Ursodeoxycholic acid …